The President R&D of Pfizer is Exercising Options

By Carrie Williams

Yesterday it was reported that the President R&D of Pfizer (PFEResearch Report), Mikael Dolsten, exercised options to buy 309,462 PFE shares at $30.75 a share, for a total transaction value of $9.52M.

This recent transaction increases Mikael Dolsten’s holding in the company by 2546.38% to a total of $15.59 million. Following Mikael Dolsten’s last PFE Buy transaction on March 03, 2017, the stock climbed by 10.8%.

See today’s analyst top recommended stocks >>

Based on Pfizer’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $13.98 billion and GAAP net loss of $394 million. In comparison, last year the company earned revenue of $13.7 billion and had a net profit of $12.27 billion. Currently, Pfizer has an average volume of 25.84M. PFE’s market cap is $245.4B and the company has a P/E ratio of 23.03.

Based on 8 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $46.88, reflecting a 9.3% upside. Four different firms, including Argus Research and Merrill Lynch, currently also have a Buy rating on the stock.

In the last 30 days, insiders have sold $1.81M worth of PFE shares and purchased $9.52M worth of PFE shares.

Mikael Dolsten’s trades have generated a -3.9% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.